• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Ozop Surgical Corp. Announces Acquisition of Established Distribution Company

Share:

July 29, 2018

OZOP Gains foothold into China market for its products

WEST PALM BEACH, Fla., July 25, 2018 – Ozop Surgical Corp. announced it acquired on July 23, 2018, 100% of the equity of Yijingtong (Beijing) Technology Development Ltd., a Chinese distributor of minimally invasive surgical products to the orthopedic and neurosurgical markets. The purchase price was RMB 1,000,000 (approximately US$147,815) payable in cash within 120 days of closing, in addition to inventory valued at RMB 4,072,719 (approximately US$ 602,009), which the parties will separately agree to payment and delivery terms. Yijingtong has achieved solid operational performance for over a decade. This company will serve as our primary trading and distribution platform in China, promoting the Company’s existing and new products and other complimentary products it plans to distribute.

Michael Chermak, OZOP’s Chief Executive Officer, commented on the acquisition, “this is an exciting development. We have a long working history and familiarity with this company and the management team. Yijingtong possesses CFDA business licenses, for class 1, 2 and 3 products, which allows it to sell virtually any medical device in China including orthopedic implants. Yijingtong provides us a proven, established platform with local Chinese infrastructure and know-how which we expect to greatly speed up the introduction and sale of our products facilitating our access to the China market, where the penetration of MIS in spine surgery is far greater than the US. Furthermore, Yijingtong has built long term relationships with key opinion leaders in our field throughout China which we intend to fully leverage. This transaction is both accretive and a vertical integration.”

Safe Harbor Statement

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

This news release contains statements that involve expectations, plans or intentions (such as those relating to our marketing efforts, future business or financial results) and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as “may,” “should,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan” and other similar expressions. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Date: July 30, 2018

Source: FOX8live

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • PatchAI and Roche Italia Launch Virtual Platform for Oncology PatientsPatchAI and Roche Italia Launch Virtual Platform for Oncology Patients
  • IBM and Boehringer Ingelheim Partner on Generative AI for Transformative Antibody TherapeuticsIBM and Boehringer Ingelheim Partner on Generative AI for Transformative Antibody Therapeutics
  • Latest AI Drug Discovery Partnership in South Korea to Tackle TuberculosisLatest AI Drug Discovery Partnership in South Korea to Tackle Tuberculosis
  • Centene : Announces Purchase Of Expanded Stake In Ribera SaludCentene : Announces Purchase Of Expanded Stake In Ribera Salud
  • Google Reveals LLM That Helps Accurately Diagnosis Complex CasesGoogle Reveals LLM That Helps Accurately Diagnosis Complex Cases
  • Sherlock Biosciences raises $31M to apply CRISPR technology to diagnosticsSherlock Biosciences raises $31M to apply CRISPR technology to diagnostics
  • AppliedVR Clears Major Regulatory Hurdle to Use Virtual Reality to Treat Chronic PainAppliedVR Clears Major Regulatory Hurdle to Use Virtual Reality to Treat Chronic Pain
  • Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization TransactionViracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications